Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 7834035, 8 pages
https://doi.org/10.1155/2017/7834035
Research Article

Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients

1Department of Pharmacy, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
2Department of Pharmacy, Jiangwan Hospital of Shanghai Hongkou District, Shanghai, China
3Department of General Surgery, Shanghai First People’s Hospital, Shanghai Jiaotong University, Shanghai, China
4Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

Correspondence should be addressed to Junwei Fan; moc.361@tenwjf and Gening Jiang; moc.361@1211ngj

Received 30 July 2016; Accepted 1 November 2016; Published 26 January 2017

Academic Editor: Gad Rennert

Copyright © 2017 Xiaoqing Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. A. Whitson and D. Hayes, “Indications and outcomes in adult lung transplantation,” Journal of Thoracic Disease, vol. 6, no. 8, pp. 1018–1023, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Hartert, Ö. Senbaklavaci, B. Gohrbandt, B. M. Fischer, R. Buhl, and C.-F. Vahl, “Lung transplantation: a treatment option in end-stage lung disease,” Deutsches Arzteblatt International, vol. 111, no. 7, pp. 107–116, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. S. D. Nathan, “The future of lung transplantation,” Chest, vol. 147, no. 2, pp. 309–316, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. Witt, V. Puri, A. E. Gelman, A. S. Krupnick, and D. Kreisel, “Lung transplant immunosuppression—time for a new approach?” Expert Review of Clinical Immunology, vol. 10, no. 11, pp. 1419–1421, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. J. L. Scheffert and K. Raza, “Immunosuppression in lung transplantation,” Journal of Thoracic Disease, vol. 6, no. 8, pp. 1039–1053, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Afshar, “Future direction of immunosuppression in lung transplantation,” Current Opinion in Organ Transplantation, vol. 19, no. 6, pp. 583–590, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Wang, H. L. McLeod, and R. M. Weinshilboum, “Genomics and drug response,” New England Journal of Medicine, vol. 364, no. 12, pp. 1144–1153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. A. Hesselink, R. Bouamar, L. Elens, R. H. N. Van Schaik, and T. Van Gelder, “The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation,” Clinical Pharmacokinetics, vol. 53, no. 2, pp. 123–139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Van Gelder, R. H. Van Schaik, and D. A. Hesselink, “Practicability of pharmacogenetics in transplantation medicine,” Clinical Pharmacology and Therapeutics, vol. 95, no. 3, pp. 262–264, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. S. S. Nair, S. Sarasamma, N. Gracious, J. George, T. S. N. Anish, and R. Radhakrishnan, “Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level,” Experimental and Clinical Transplantation, vol. 13, pp. 197–200, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. L. E. Rojas, M. J. Herrero, V. Bosó et al., “Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation,” Pharmacogenetics and Genomics, vol. 23, no. 10, pp. 509–517, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Z. Vahed, M. Ardalan, N. Samadi, and Y. Omidi, “Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients,” BioImpacts, vol. 5, no. 1, pp. 45–54, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Monchaud, B. C. De Winter, C. Knoop et al., “Population pharmacokinetic modelling and design of a bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation,” Clinical Pharmacokinetics, vol. 51, no. 3, pp. 175–186, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Zheng, A. Zeevi, E. Schuetz et al., “Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism,” Journal of Clinical Pharmacology, vol. 44, no. 2, pp. 135–140, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Provenzani, A. Santeusanio, E. Mathis et al., “Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients,” World Journal of Gastroenterology, vol. 19, no. 48, pp. 9156–9173, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. C.-M. Lee, J. Pohl, and E. T. Morgan, “Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures S,” Drug Metabolism and Disposition, vol. 37, no. 4, pp. 865–872, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Westerholt, S. Himpel, B. Hager-Gensch et al., “Intragraft iNOS induction during human liver allograft rejection depresses cytochrome p450 activity,” Transplant International, vol. 17, no. 7, pp. 370–378, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Li, J.-Y. Zhu, J. Gao, X. Wang, Y.-Q. Lou, and G.-L. Zhang, “Polymorphisms of tumor necrosis factor-α, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus,” Clinica Chimica Acta, vol. 383, no. 1-2, pp. 133–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Li, W. Lu, J.-Y. Zhu, J. Gao, Y.-Q. Lou, and G.-L. Zhang, “Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients,” Journal of Clinical Pharmacy and Therapeutics, vol. 32, no. 5, pp. 505–515, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Zhang, Z. Wang, J. Fan, G. Liu, and Z. Peng, “Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period,” European Journal of Clinical Pharmacology, vol. 67, no. 8, pp. 803–813, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C.-J. Li, L. Li, L. Lin et al., “Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients,” PLoS ONE, vol. 9, no. 1, Article ID e86206, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Li, Y. Zou, B. Cai et al., “The associations of IL-18 serum levels and promoter polymorphism with tacrolimus pharmacokinetics and hepatic allograft dysfunction in Chinese liver transplantation recipients,” Gene, vol. 491, no. 2, pp. 251–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Fan, X. Zhang, L. Ren et al., “Donor IL-18 rs5744247 polymorphism as a new biomarker of tacrolimus elimination in Chinese liver transplant patients during the early post-transplantation period: results from two cohort studies,” Pharmacogenomics, vol. 16, no. 3, pp. 239–250, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Xing, X. Zhang, J. Fan, B. Shen, T. Men, and J. Wang, “Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients,” European Journal of Clinical Pharmacology, vol. 71, no. 2, pp. 191–198, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Li, Z. Zhang, Z. He et al., “A partition-ligation-combination-subdivision em algorithm for haplotype inference with multiallelic markers: Update of the SHEsis (http://analysis.bio- x.cn),” Cell Research, vol. 19, no. 4, pp. 519–523, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Gatault, M. Delbeke, V. Driss et al., “IL-18 is involved in eosinophil-mediated tumoricidal activity against a colon carcinoma cell line by upregulating LFA-1 and ICAM-1,” The Journal of Immunology, vol. 195, no. 5, pp. 2483–2492, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. L. E. Rojas, M. J. Herrero, V. Bosó et al., “Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation,” Pharmacogenetics and Genomics, vol. 23, no. 10, pp. 509–517, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. H. de Jonge and D. R. J. Kuypers, “Pharmacogenetics in solid organ transplantation: current status and future directions,” Transplantation Reviews, vol. 22, no. 1, pp. 6–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. T.-C. Hsia, W.-S. Chang, S.-J. Liang et al., “Interleukin-10 (IL-10) promoter genotypes are associated with lung cancer risk in Taiwan males and smokers,” Anticancer Research, vol. 34, no. 12, pp. 7039–7044, 2014. View at Google Scholar · View at Scopus
  30. W.-H. Kuo, C.-Y. Huang, C.-K. Fu et al., “Effects of interleukin-10 polymorphisms and smoking on the risk of gastric cancer in Taiwan,” In Vivo, vol. 28, no. 5, pp. 967–972, 2014. View at Google Scholar · View at Scopus
  31. S. Lee, G. R. Abecasis, M. Boehnke, and X. Lin, “Rare-variant association analysis: study designs and statistical tests,” American Journal of Human Genetics, vol. 95, no. 1, pp. 5–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. V. R. Mas, R. A. Fisher, D. G. Maluf et al., “Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation,” Clinical Genetics, vol. 65, no. 3, pp. 191–201, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Y. Xie, W. L. Wang, M. Y. Yao et al., “Polymorphisms in cytokine genes and their association with acute rejection and recurrence of hepatitis B in Chinese liver transplant recipients,” Archives of Medical Research, vol. 39, no. 4, pp. 420–428, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Xiong, Y. Wang, Y. Zhang et al., “Lack of association between interleukin-10 gene polymorphisms and graft rejection risk in kidney transplantation recipients: a meta-Analysis,” PLoS ONE, vol. 10, no. 6, Article ID e0127540, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Liu, B. Li, W.-T. Wang et al., “Interleukin-10-1082G/A polymorphism and acute liver graft rejection: a meta-analysis,” World Journal of Gastroenterology, vol. 18, no. 8, pp. 847–854, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. H.-J. Mu, P. Xie, J.-Y. Chen et al., “Association of TNF-α, TGF-β1, IL-10, IL-6, and IFN-γ gene polymorphism with acute rejection and infection in lung transplant recipients,” Clinical Transplantation, vol. 28, no. 9, pp. 1016–1024, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Harada, K. Obara, T. Hirota et al., “A functional polymorphism in IL-18 is associated with severity of bronchial asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 11, pp. 1048–1055, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. V. Dziedziejko, M. Kurzawski, E. Paczkowska, B. Machalinski, and A. Pawlik, “The impact of IL18 gene polymorphisms on mRNA levels and interleukin-18 release by peripheral blood mononuclear cells,” Postepy Higieny i Medycyny Doswiadczalnej, vol. 66, pp. 409–414, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Tsutsui and K. Nakanishi, “Immunotherapeutic applications of IL-18,” Immunotherapy, vol. 4, no. 12, pp. 1883–1894, 2012. View at Publisher · View at Google Scholar · View at Scopus